Journal Mobile Options
Table of Contents
Vol. 118, No. 2-4, 1999
Issue release date: February–April 1999

The CC Chemokine Receptor Antagonist Met–RANTES Inhibits Eosinophil Effector Functions

Elsner J. · Petering H. · Kimmig D. · Wells T.N.C. · Proudfoot A.E.J. · Kapp A.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Eosinophils play an important role in allergic diseases such as allergic asthma, rhinoconjunctivitis and atopic dermatitis. Recruitement of eosinophils to the side of inflammation, the release of reactive oxygen species, leading to tissue damage, and the propagation of the inflammatory response are mediated by chemokines. Thus, the applicability of agents able to inhibit or antagonize chemokine–induced eosinophil activation seems to be of interest in the treatment of allergic diseases. Therefore, the effect of the CC chemokine antagonist, Met–RANTES, on its effect on human eosinophil effector functions in response to RANTES, MCP–3 and eotaxin was investigated. Met–RANTES had no intrinsic activity on [Ca2+]i transients in eosinophils and was able to dose–dependently inhibit [Ca2+]i transients in eosinophils following stimulation with RANTES, MCP–3 and eotaxin. Besides its effect on [Ca2+]i transients, Met–RANTES dose–dependently inhibited actin polymerization in eosinophils and the release of reactive oxygen species following stimulation with RANTES, MCP–3 and eotaxin. The results of this study lead to the conclusion that Met–RANTES is an effective and powerful compound to antagonize effector functions of human eosinophils following stimulation with RANTES, MCP–3 and eotaxin and is therefore a promising therapeutic approach to prevent the invasion and destructive power of eosinophils in allergic diseases.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Kapp A: Atopic dermatitis – The skin manifestation of atopy. Clin Exp Allergy 1995;25: 210–219.

    External Resources

  2. Wardlaw AJ, Moqbel R, Kay AB: Eosinophils: Biology and role in disease. Adv Immunol 1995;60:151–266.
  3. Aractingi S, Janin A, Zini JM, Gauthier MS, Chauvenet L, Tobelem G, Prin L, Chosidow O, Frances C: Specific mucosal erosions in hypereosinophilic syndrome: Evidence for eosino–phil protein deposition. Arch Dermatol 1996; 132:535–541.
  4. Czech W, Schaller J, Schöpf E, Kapp A: Granulocyte activation in bullous diseases – Release of granular proteins in bullous pemphigoid and pemphigus vulgaris. J Am Acad Dermatol 1993;29:210–215.
  5. Dhami D, Shutte JK: Mechanisms of epithelial damage: Are there parallels between bullous skin diseases and asthma? Clin Exp Allergy 1994;24:1005.

    External Resources

  6. Grewe M, Bruijnzeel–Koomen CAFM, Schöpf E, Thepen T, Langeveld–Wildschut AG, Ruzicka T, Krutmann J: A role for Th1 and Th2 cells in the immunopathogenesis of atopic dermatitis. Immunol Today 1998;19:359–361.
  7. Bieber T, de la Salle H, Wollenberg A, Hakimi J, Chizzonite R, Ring J, Hanau D, de la Salle C: Human epidermal Langerhans cells express the high affinity receptor for immunoglobulin E (Fc epsilon RI). J Exp Med 1993;175: 1285–1290.
  8. Gleich GJ, Adolphoson CR, Leifermann KM: The biology of the eosinophilic leukocyte. Annu Rev Med 1993;44:85–101.
  9. Busse WW, Sedgwick JB: Eosinophils in asthma. Ann Allergy 1992;286:286–290.
  10. Rochester CL, Ackermann SJ, Zheng T, Elias JA: Eosinophil–fibroblast interactions – Granule major basic protein interacts with IL–1 and transforming growth factor–beta in the stimulation of lung fibroblast IL–6–type cytokine production. J Immunol 1996;156:4449–4456.

    External Resources

  11. Schröder JM, Noso N, Sticherling M, Christophers E: Role of eosinophil–chemotactic C–C chemokines in cutaneous inflammation. J Leu–koc Biol 1996;59:1–5.
  12. Coyle AJ, Ackermann S, Burch R, Proud D, Irvin CG: Human eosinophil granule major basic protein and synthetic polycations induce airway hyperresponsiveness in vivo dependent on bradykinin generation. J Clin Invest 1995; 95:1735–1740.
  13. Ying S, Taborda Barata L, Meng Q, Humbert M, Kay AB: The kinetics of allergen–induced transcription of messenger RNA for monocyte chemotactic protein–3 and RANTES in the skin of human atopic subjects: Relationship to eosinophil, T cell, and macrophage recruitment. J Exp Med 1995;181:2153–2159.

    External Resources

  14. Elsner J, Dichmann S, Kapp A: Activation of the respiratory burst in human eosinophils by chemotaxins requires intracellular calcium fluxes. J Invest Dermatol 1995;105:231–236.

    External Resources

  15. Kapp A: The role of eosinophils in the pathogenesis of atopic dermatitis – Eosinophil granule proteins as markers of disease activity. Allergy 1993;48:1–5.
  16. Elsner J, Hochstetter R, Spiekermann K, Kapp A: Surface and mRNA expression of the CD52 antigen by human eosinophils but not by neutrophils. Blood 1996;88:4684–4693.
  17. Elsner J, Oppermann M, Kapp A: Detection of C5a receptors on human eosinophils and inhibition of eosinophil effector functions by anti–C5a receptor (CD88) antibodies. Eur J Immunol 1996;26:1560–1564.

    External Resources

  18. Elsner J, Oppermann M, Czech W, Kapp A: C3a activates the respiratory burst in human polymorphonuclear neutrophilic leukocytes via pertussis toxin–sensitive G–proteins. Blood 1994;83:3324–3331.
  19. Elsner J, Oppermann M, Czech W, Dobos G, Schöpf E, Norgauer J, Kapp A: C3a activates reactive oxygen radical species production and intracellular calcium transients in human eosinophils. Eur J Immunol 1994;24:518–522.

    External Resources

  20. Zeck Kapp G, Kroegel C, Riede UN, Kapp A: Mechanisms of human eosinophil activation by complement protein C5a and platelet–activating factor: Similar functional responses are accompanied by different morphologic alterations. Allergy 1995;50:34–47.
  21. Baggiolini M: Chemokines and leukocyte traffic. Nature 1998;392:565–568.
  22. Moser B, Loetscher M, Piali L, Loetscher P: Lymphocyte responses to chemokines. Int Rev Immunol 1998;16:323–344.

    External Resources

  23. Luster AD: Chemokines – chemotactic cyto–kines that mediate inflammation. N Engl J Med 1998;338:436–445.
  24. Kapp A, Zeck Kapp G, Czech W, Schöpf E: The chemokine RANTES is more than a chemoattractant: Characterization of its effect on human eosinophil oxidative metabolism and morphology in comparison with IL–5 and GM–CSF. J Invest Dermatol 1994;102: 906– 914.
  25. Elsner J, Hochstetter R, Kimmig D, Kapp A: Human eotaxin represents a potent activator of the respiratory burst of human eosinophils. Eur J Immunol 1996;26:1919–1925.
  26. Petering H, Hochstetter R, Kimmig D, Smolarski R, Kapp A, Elsner J: Detection of MCP–4 in dermal fibroblasts and its activation of the respiratory burst in human eosinophils. J Immunol 1998;160:555–558.

    External Resources

  27. Elsner J, Petering H, Kluthe C, Kimmig D, Smolarski R, Ponath P, Kapp A: Eotaxin–2 activates chemotaxis–related events and release of reactive oxygen species via pertussis toxin–sensitive G proteins in human eosinophils. Eur J Immunol 1998;28:2152–2158.
  28. Gong JH, Clark–Lewis I: Antagonists of monocyte chemoattractant protein 1 identified by modification of functionally critical NH2–ter–minal residues. J Exp Med 1995;181:631–640.

    External Resources

  29. Weber M, Uguccioni M, Baggiolini M, Clark Lewis I, Dahinden CA: Deletion of the NH2–terminal residue converts monocyte chemotactic protein 1 from an activator of basophil me– diator release to an eosinophil chemoattrac–tant. J Exp Med 1996;183:681–685.

    External Resources

  30. Wells TNC, Power CA, Lusti–Narasimhan M, Hoogewerf AJ, Cooke RM, Chung C, Peitsch MC, Proudfoot AEI: Selectivity and antagonism of chemokine receptors. J Leukoc Biol 1996;59:53–60.
  31. Proudfoot AE, Power CA, Hoogewerf AJ, Montjovent MO, Borlat F, Offord RE, Wells TN: Extension of recombinant human RANTES by the retention of the initiating methionine produces a potent antagonist. J Biol Chem 1996;271:2599–2603.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50